Yerkhanat Khuanbai

Dr. Yerkhanat Khuanbai

Professor G.V. Tsoi Scientific and Educational Center for Surgery, Astana Medical University, Nur-Sultan, Astana, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SAShiirevnyamba Avirmed
Shiirevnyamba Avirmed
Yerkhanat KhuanbaiYerkhanat Khuanbai
Yerkhanat Khuanbai
ASAmarsaikhan Sanjaajamts
Amarsaikhan Sanjaajamts
BSBaasansuren Selenge
Baasansuren Selenge
BDBayan-Undur Dagvadorj
Bayan-Undur Dagvadorj
MOMakoto Ohashi
Makoto Ohashi
Objectives: Tobacco smoking is the predominant risk factor for bladder cancer as it contains cancer-causing chemicals. However, genetic factors may play important role in response towards chemical carcinogens. In this study we aim to investigate genetic polymorphisms of glutathione S-transferase M1 (GSTM1) and N-acetyltransferase 2 (NAT2) as determinants of bladder cancer risk, independently and in combination with tobacco use in the Mongolian population. Materials and Methods: The current study was a hospital-based case-control study including 60 histologically confirmed bladder cancer patients and 60 cancer-free controls. PCR-RFLP assay was used to determine the presence of GSTM1 and NAT2 polymorphisms in bladder cancer patients and controls. GSTM1 and NAT2 were tested using binary logistical regression analysis with adjustment or stratification according to the smoking. Results: There were 46 men and 14 women diagnosed with bladder cancer, with mean age was 58±4. The controls included 37 men and 23 women with a mean age of 57±3. The frequency of GSTM1 null genotype was higher in controls (71.67%) than in bladder cancer patients (58.33%) without statistical significance (OR=0.5534; 95% CI=0.2586-1.1843), (p=0.128). The NAT2 low acetylator phenotype was more common in patients with bladder cancer (15%) than in controls (5%). Furthermore, individuals with NAT2 low acetylator phenotype had a nearly 3.35-fold increased risk to develop bladder cancer (OR=3.35; 95% CI=0.8604-13.0657), (p=0.081) while the risk was even higher when combined with null GSTM1 genotype (OR=4; 95% CI=0.4459-37.5308), (p=0.213) but there was no statistical significance. Prevalence of smoking in bladder cancer patients was higher than controls and increased significantly the risk of bladder cancer (OR=8.31; 95% CI=3.66-18.88). Smokers with GSTM1 null genotype were at 5-fold higher risk of bladder cancer (OR=5.0; 95% CI=1.55-16.16), (p=0.007) while NAT2 low acetylator phenotype increased bladder cancer risk by 20-fold (OR=20.5; 95% CI=2.33-80.86), (p=0.006). Conclusion: The current study shows that tobacco smokers with the NAT2 low acetylator phenotype and GSTM1 null genotype have the highest risk of bladder cancer in the Mongolian population.

Verified
Journal Article
Open access
PDF file
DSDarya Shafiee
Darya Shafiee
ZSZhandos Salpynov
Zhandos Salpynov
AGArnur Gusmanov
Arnur Gusmanov
Yerkhanat KhuanbaiYerkhanat Khuanbai
Yerkhanat Khuanbai
ZMZhussipbek Mukhatayev
Zhussipbek Mukhatayev
JKJeannette Kunz
Jeannette Kunz
Background. The objective of this systematic review and meta-analysis was to estimate the proportions of individuals infected with Campylobacter, Escherichia, Salmonella, Shigella, or Yersinia who develop reactive arthritis. Methods. A systematic review was conducted, encompassing English-language articles published before January 2024, sourced from the Embase, PubMed, Scopus, and Web of Science databases. This review included observational studies that reported the occurrence of reactive arthritis (ReA) among patients with Campylobacter, Escherichia, Salmonella, Shigella, or Yersinia infections. Data extraction was carried out independently by two reviewers. Subsequently, a random-effects meta-analysis was performed, with heterogeneity assessed using the I2 value. Additionally, meta-regression was employed to investigate the potential influence of study-level variables on the observed heterogeneity. Results. A total of 87 studies were identified; 23 reported on ReA development after Campylobacter infection, 7 reported on ReA after Escherichia infection, 30 reported ReA onset after salmonellosis, 14 reported ReA after shigellosis, and 13 reported ReA after Yersinia infection. The proportion of Campylobacter patients who developed ReA was 0.03 (95% CI [0.01, 0.06], I2 = 97.62%); the proportion of Escherichia patients who developed ReA was 0.01 (95% CI [0.00, 0.06], I2 = 92.78%); the proportion of Salmonella patients was 0.04 (95% CI [0.02, 0.08], I2 = 97.67%); the proportion of Shigella patients was 0.01 (95% CI [0.01, 0.03], I2 = 90.64%); and the proportion of Yersinia patients who developed ReA was 0.05 (95% CI [0.02, 0.13], I2 = 96%). Conclusion. A significant proportion of Salmonella, Shigella, and Yersinia cases resulted in ReA. Nonetheless, it is important to interpret the findings cautiously due to the substantial heterogeneity observed between studies.

22 July 2026 in Nature
Verified
Journal Article
Closed access
PDF file
GCGbd 2023 Asia Life Expectancy Collaborators
Gbd 2023 Asia Life Expectancy Collaborators
JKJiseung Kang
Jiseung Kang
HKHyeon Jin Kim
Hyeon Jin Kim
MKMin Seo Kim
Min Seo Kim
JAJeofrey Bautista Abalos
Jeofrey Bautista Abalos
NSNicholas Steel
Nicholas Steel

19 February 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ZMZhussipbek Mukhatayev
Zhussipbek Mukhatayev
AKArtur Kovenskiy
Artur Kovenskiy
ZRZiyou Ren
Ziyou Ren
SRStephanie M. Rangel
Stephanie M. Rangel
NKNurlubek Katkenov
Nurlubek Katkenov
IPI. Caroline Le Poole
I. Caroline Le Poole

19 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Yerkhanat KhuanbaiYerkhanat Khuanbai
Yerkhanat Khuanbai
BRBerik Rovgaliyev
Berik Rovgaliyev
TKTlek Karimov
Tlek Karimov
RKRuslan Khassenov
Ruslan Khassenov
SKSaken Kozhakhmetov
Saken Kozhakhmetov
Background: Gallstone ileus is an uncommon cause of mechanical intestinal obstruction that predominantly affects older adults. It results from migration of a gallstone through a biliary–enteric fistula, most commonly a cholecystoduodenal fistula. Methods: An 84-year-old woman with hypertension and hypothyroidism presented with a four-day history of right upper quadrant abdominal pain, nausea, and vomiting. Laboratory investigations showed a marked inflammatory response and severe renal dysfunction with a substantial reversible acute component, most likely related to volume depletion and reduced renal perfusion. Computed tomography demonstrated an ectopic gallstone impacted in the distal small bowel, proximal bowel dilatation, pneumobilia, and a cholecystoduodenal fistula. Emergency laparotomy confirmed gallstone ileus. After assessment of the operative risk and local anatomy, a one-stage procedure was performed, comprising enterolithotomy, cholecystectomy, division of the fistula, and primary repair of the duodenal defect. Results: Postoperative management included continued monitoring of the admission renal dysfunction, together with treatment of postoperative tracheobronchitis, anemia, electrolyte disturbances, and transient elevation in pancreatic enzymes. These abnormalities were managed with supportive and multidisciplinary care. Renal function, inflammatory markers, and electrolyte concentrations improved substantially before discharge. Pancreatic amylase returned to its reference interval, whereas total α-amylase was below its stated reference interval at discharge, although anemia persisted. The patient was discharged in satisfactory condition on postoperative day 13. Conclusions: Computed tomography enabled preoperative diagnosis and characterization of the cholecystoduodenal fistula. Although a one-stage operation was feasible in this patient, this single outcome does not establish its superiority. Surgical management should be individualized according to the patient’s physiological condition, comorbidities, and intraoperative findings.

1 November 2020 in European Urology Open Science
Verified
Journal Article
Open access
Yerkhanat KhuanbaiYerkhanat Khuanbai
Yerkhanat Khuanbai
SAS. Avirmed
S. Avirmed